Your gut microbiome may predict whether you'll get a fever after an mRNA vaccine

Key Findings

🧬 Poly(A) tails get a second job: silencing mRNA in the wrong cells

• Researchers inserted microRNA target sites into segmented poly(A) tails on synthetic mRNA and showed they could suppress protein expression in non-target cell types while preserving it in the intended cells—in both lab and animal models.
• Using triple microRNA target sequences, specific insertion arrangements simultaneously reduced activity in three non-target liver cell types without touching hepatocyte expression. Insertion order turned out to matter, which wasn't seen in simpler two-target designs.

💉 A Zika mRNA vaccine separated protection from a dangerous dengue side effect in monkeys

• An engineered Zika mRNA vaccine produced antibodies that were more than 97% Zika-specific in macaques, with negligible antibody-dependent enhancement of dengue—a safety problem that has plagued flavivirus vaccine development.
• The antibodies targeted a vulnerable hotspot on the Zika virus, and cross-reactivity with dengue was blocked by a single sugar modification on dengue's surface. The dominant antibody population matched one preferentially recruited during natural human Zika infection.

🫁 Adding lung surfactant to LNPs boosted lung mRNA delivery about tenfold

• Incorporating Poractant alfa—a clinically used lung surfactant cocktail—into lipid nanoparticles produced roughly 10 times more particles at equivalent input conditions compared to conventional formulations, with several-fold increases in mRNA transfection efficiency in cell studies.
• In mice, intranasal delivery of surfactant-enhanced LNPs produced stronger protein expression in lung tissue than standard LNPs. The improvement was attributed to a higher apparent acidity and surface-active properties of surfactant protein B, which promoted faster endosomal escape.

🧠 Stroke-damaged mouse brains recovered after mRNA delivered via nose in extracellular vesicles

• Researchers loaded modified mRNA encoding Netrin-1—a neuroprotective protein—into extracellular vesicles derived from stem cells and delivered them intranasally to mice with ischemic stroke. Treated mice showed reduced infarct volume and improved neurological outcomes compared to controls.
• The neuroprotection was associated with activation of a specific cell-survival signaling pathway in neurons. The approach bypasses the blood-brain barrier without surgery, which remains a major obstacle for brain-targeted RNA therapies.

🐷 An 8-antigen influenza mRNA vaccine protected pigs against a mismatched strain

• A multivalent mRNA-LNP vaccine encoding eight hemagglutinin proteins—selected to cover 95% of influenza A strains detected in U.S. swine between 2022 and 2025—induced neutralizing antibodies against all eight antigens in piglets and protected against lung lesions after challenge with a field strain.
• Heterologous monovalent vaccination didn't cross-protect but also didn't cause vaccine-associated enhanced respiratory disease, an important safety signal in swine influenza research.

⚠️ High-dose mRNA-LNP shifted bone marrow cell production—but it reversed within two weeks

• At deliberately supra-clinical doses in mice and non-human primates, mRNA formulated in lipid nanoparticles transiently suppressed red blood cell precursors and expanded granulocyte production in bone marrow. The effect required mRNA inside the LNP—naked mRNA or LNP alone didn't fully replicate it.
• Blocking type I interferon signaling prevented the shift, identifying the mechanism. The bone marrow returned to normal within two weeks, but the finding adds a monitoring consideration for high-dose systemic mRNA applications.